Association of clinical features and intratumoral lymphocyte infiltration with TLS
| Clinical variables | TLSneg | TLS+ | P value |
| Patients (n=64) | 34 | 30 | -- |
| Median age | 61.3 | 56.0 | 0.66 |
| Female sex | 19 (58%) | 19 (63%) | 0.73 |
| Curative intent at resection | 17 (50%) | 21 (70%) | 0.17 |
| Immunotype A | 15 (44%) | 6 (20%) | 0.13* |
| Immunotype B | 17 (50%) | 21 (70%) | |
| Immunotype C | 2 (6%) | 3 (10%) | |
| Stage 3 disease | 17 (50%) | 17 (57%) | 0.78 |
| Stage 4 disease | 17 (50%) | 13 (43%) | |
| Disease recurrence† | 33 (97%) | 23 (77%) | 0.02* |
| Intratumoral Immune Infiltrate (cells/mm2) (mean) | |||
| CD3 +T cells | 90.8 | 197.9 | 0.01 |
| CD4 +T cells | 31.8 | 45.4 | 0.10 |
| CD8 +T cells | 68.7 | 152.7 | 0.01 |
| CD20 +B cells | 7.1 | 24.4 | <0.01 |
| CD138 +plasma cells | 6.0 | 44.9 | <0.01 |
| FoxP3 +Treg cells | 12.0 | 25.4 | 0.12 |
| CD45 +immune cells | 106.1 | 274.1 | <0.01 |
*Fisher’s exact test, otherwise, p values from Mann-Whitney U tests or χ2 tests, as appropriate, with clinical information as recorded at time of metastasectomy.
†Recurrence determined at time of last follow up.
‡Bold indicates p-value <0.05.
TLS, tertiary lymphoid structure; Treg, regulatory T cells.